BRAF and neoplasm: In the case of the wild-type BRAF SK23-MEL cells, both treatments induceda certain degree of delay in tumor growth (Fig. 7B, left panel), but nonetheless effects appeared quite limited, anddid not result in an improvement in survival (ILS < 20%) (Fig. 7B, right panel).